跳至主要内容
临床试验/EUCTR2020-004966-20-AT
EUCTR2020-004966-20-AT进行中(未招募)1 期

A GLP-1 receptor PET imaging add-on study within the Ver-A-T1D trialinvestigating the effects of Verapamil or placebo on beta cell mass (ImageVer-A-T1D) - Image-VER-A-T1D

Radboud University Medical Center0 个研究点目标入组 30 人开始时间: 2021年5月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Have given written informed consent
  • - Are aged between 18 and 45 years old
  • - Are included in the VER-A-T1D trial
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Treatment with synthetic exendin (Exentide, Byetta®) or dipeptidyl-peptidase IV inhibitors (to exclude interferences with imaging), specifically mentioned although in principle part of exclusion criteria VER-A-T1D.
  • Renal disease defined as MDRD < 40 ml/min/1.73m2
  • Pregnancy or the wish to become pregnant within 2 months after second PET/CT scan.

研究者

相似试验